Redeye: Saniona Q4 2022 - Transformational year
Redeye returns with a research update following the Q4 report and recent events in the company. We reiterate our base case and conclude that 2022 was a transformational year for the company, for both good and bad. We see good prospect for positive momentum in the share during 2023 if Saniona delivers on its agenda.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/